Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Holtzman

Showing results (31-40 of 602) with videos related to

Pageof 61
Sort By:
Science Translational Medicine|November 8, 2023
Current status of amyloid-targeting immunotherapies for Alzheimer's diseaseG Travis Tabor, David M Holtzman
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|November 19, 2019
Gut Microbiota: From the Forgotten Organ to a Potential Key Player in the Pathology of Alzheimer's DiseaseDong-Oh Seo, David M Holtzman
The Journal of Clinical Investigation|February 12, 2019
Dr. Jekyll and Mr. Hyde: ApoE explains opposing effects of neuronal LRP1Michael R Strickland, David M Holtzman
Annals of Neurology|January 14, 2015
Apolipoprotein E levels and Alzheimer riskBradley T Hyman, David M Holtzman
Biomarkers in Medicine|April 3, 2010
Cerebrospinal fluid biomarkers of Alzheimer's diseaseAnne M Fagan, David M Holtzman
Neurology|January 12, 2005
Immunization therapy for Alzheimer disease?David A Bennett, David M Holtzman
Neuron|July 26, 2005
The bad seed in Alzheimer's diseaseJohn D Fryer, David M Holtzman
Neuron|December 24, 2013
Biomarker modeling of Alzheimer's diseaseClifford R Jack, David M Holtzman
EMBO Molecular Medicine|March 16, 2016
CSF sTREM2: marking the tipping point between preclinical AD and dementia?Suzanne E Schindler, David M Holtzman
The Journal of Experimental Medicine|April 25, 2018
Dual therapy for Aβ amyloidosis in AD: A successful one-two comboTirth K Patel, David M Holtzman
Pageof 61

Showing results (31-40 of 602) with videos related to

Sort By:
Pageof 61
Science Translational Medicine|November 8, 2023
Current status of amyloid-targeting immunotherapies for Alzheimer's diseaseG Travis Tabor, David M Holtzman
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|November 19, 2019
Gut Microbiota: From the Forgotten Organ to a Potential Key Player in the Pathology of Alzheimer's DiseaseDong-Oh Seo, David M Holtzman
The Journal of Clinical Investigation|February 12, 2019
Dr. Jekyll and Mr. Hyde: ApoE explains opposing effects of neuronal LRP1Michael R Strickland, David M Holtzman
Annals of Neurology|January 14, 2015
Apolipoprotein E levels and Alzheimer riskBradley T Hyman, David M Holtzman
Biomarkers in Medicine|April 3, 2010
Cerebrospinal fluid biomarkers of Alzheimer's diseaseAnne M Fagan, David M Holtzman
Neurology|January 12, 2005
Immunization therapy for Alzheimer disease?David A Bennett, David M Holtzman
Neuron|July 26, 2005
The bad seed in Alzheimer's diseaseJohn D Fryer, David M Holtzman
Neuron|December 24, 2013
Biomarker modeling of Alzheimer's diseaseClifford R Jack, David M Holtzman
EMBO Molecular Medicine|March 16, 2016
CSF sTREM2: marking the tipping point between preclinical AD and dementia?Suzanne E Schindler, David M Holtzman
The Journal of Experimental Medicine|April 25, 2018
Dual therapy for Aβ amyloidosis in AD: A successful one-two comboTirth K Patel, David M Holtzman
Pageof 61